Michelle McCloskey
Family · New Orleans, LANPI 1598010605
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,234 and has fallen 59.4% since, to $907 in 2025. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $63.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$1K
- Boston Scientific$1K
- Abbott$752
- Medtronic$549
- Dexcom, Inc.$526
- AbbVie$440
- plus $4K from 30 others
What the payments were for
- Food & beverage$7,81296%
- Education$3504%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 27 | $1,080 |
| Boston Scientific | 21 | $1,041 |
| Abbott | 13 | $752 |
| Medtronic | 5 | $549 |
| Dexcom, Inc. | 4 | $526 |
| AbbVie | 7 | $440 |
| Gilead | 4 | $392 |
| AstraZeneca(2 entities) | 3 | $364 |
| Teva Pharmaceuticals USA, Inc. | 3 | $295 |
| Sanofi | 2 | $240 |
| Amgen(2 entities) | 2 | $239 |
| Neurelis, Inc. | 2 | $176 |
| Relievant Medsystems, Inc. | 4 | $157 |
| GRT US Holding, Inc. | 2 | $140 |
| Si-bone, Inc. | 1 | $130 |
| Edwards Lifesciences | 1 | $125 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Madrigal Pharmaceuticals | 1 | $123 |
| Novo Nordisk | 1 | $122 |
| Sage Therapeutics, LLC | 1 | $118 |
| Johnson & Johnson | 1 | $115 |
| Phadia US Inc. | 1 | $112 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Impel Pharmaceuticals Inc. | 1 | $100 |
| Itamar Medical Inc | 1 | $98 |
| Nalu Medical, Inc. | 2 | $96 |
| Neurocrine Biosciences, Inc. | 1 | $94 |
| Globus Medical | 4 | $87 |
| Eisai Inc. | 2 | $42 |
| Servier Pharmaceuticals LLC | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| SPR Therapeutics, Inc | 1 | $34 |
| Averitas Pharma Inc. | 1 | $27 |
| Convatec Inc. | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| BTG International Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza$456
- VRAYLAR$375
- DEXCOM G7 GSS (161)$285
- DEXCOM G6 TRANSMITTER$242
- Proclaim IPG$239
- DUPIXENT$237
- KYPHON EXPRESS II KYPHOPAK TRAY$166
- DEXCOM STELO GLUCOSE BIOSENSOR$163
- FREESTYLE LIBRE 3$148
- Intracept$144
- INTELLIS ADAPTIVESTIM$135
- FreeStyle Libre 2$128
- AJOVY$125
- Epclusa$125
- AUSTEDO$125
- Repatha$125
- UPTRAVI$125
- OPSUMIT$125
- REZDIFFRA$123
- Wegovy$122
How this compares
$8,162 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 443 | $8,610 |
| Tizanidine Hcl | 234 | $2,736 |
| Lidocaine | 13 | $1,877 |
| Duloxetine Hcl | 76 | $1,649 |
| Diclofenac Sodium | 45 | $1,119 |
| Celecoxib | 44 | $919 |
| Methocarbamol | 130 | $838 |
| Cyclobenzaprine Hcl | 96 | $801 |
| Baclofen | 48 | $509 |
| Amitriptyline Hcl | 28 | $290 |
| Ibuprofen | 16 | $148 |
| Meloxicam | 45 | $97 |
Paid to pharmacies, not to this prescriber.
Other family in New Orleans
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Amy SchmittNew Orleans$48K
- Eric BabineauxNew Orleans$32K
- Cherie AlbroNew Orleans$29K
- Aimee ScroggsNew Orleans$20K
- Kelly BaquetNew Orleans$18K
- Lori LemoineNew Orleans$17K
- Jennifer GreenheckNew Orleans$15K
- Joseph DefraitesNew Orleans$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.